Article Sidebar
Published:
Oct 3, 2018Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of immunomodulatory activity of tenoxicam in mice
Abstract
Purpose: The present study was conducted to evaluate the effect of tenoxicam on cellular and humoral immunity.
Methods: Tenoxicam (2.5 - 10mg/kg) was administered at three different doses to three groups of mice and the cellular immune responses were studied using delayed hypersensitivity response (DTH) and cyclophosphamide-induced neutropenia while the humoral immune response was evaluated using hemagglutination test and mice mortality ratio. Normal saline and cyclophosphamide were used as negative and positive controls, respectively.
Results: DTH assay resulted in a significant reduction in skin thickness (p < 0.05) for tenoxicam treated groups when compared to the negative control group at 24 h, 48 h and 72 h after administration of challenging dose of dinitrochlorobenzene (DNCB). Cyclophoshamide induced neutropenia showed a significant percentage reduction in total leukocyte count (TLC) and differential leukocyte count (DLC) i.e. lymphocytes and neutrophils (p< 0.05), but an increase in monocytes in all the treatment groups in the following order: 10 mg>5 mg >2.5 mg> negative control group. A dose dependent reduction response was observed (p<0.05) in haemagglutination assay (HA). In mice lethality test mortality ratios of 2.5 mg, 5 mg, 10 mg tenoxicam were 60 %, 80% and 100 %, respectively, compared to 20 % and 100 % for normal saline group and cyclophosphamide, respectively
Conclusion: The results suggest that tenoxicam suppresses both cellular and humoral immunity in mice.
Keywords: Tenoxicam, Cellular immunity, Humoral immunity
